Results 91 to 100 of about 6,415,892 (312)

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

open access: yesTranslational Neurodegeneration, 2019
The fundamental role that alpha-synuclein (aSyn) plays in the pathogenesis of neurodegenerative synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, is a well-accepted fact.
Naomi P. Visanji   +2 more
doaj   +1 more source

A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson’s disease [PDF]

open access: yes, 2015
Parkinson's disease (PD) is an age-associated neurodegenerative disorder hallmarked by a loss of mesencephalic dopaminergic neurons. Accurate recapitulation of the PD movement phenotype in animal models of the disease is critical for understanding ...
Geldenhuys, Werner   +9 more
core   +2 more sources

A Two‐Stage Questionnaire and Actigraphy Screening for iRBD in a Multicenter Retrospective Cohort

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid‐eye‐movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video‐polysomnography. We assessed a two‐stage screening strategy combining a brief questionnaire on rapid‐
Caleb A. Massimi   +17 more
wiley   +1 more source

Cardiac sympathetic degeneration informs the duration of the prodromal stage of body-first Lewy body disease

open access: yesnpj Parkinson's Disease
Body-first Lewy body disease (LBD) is hypothesized to begin in the peripheral autonomic nervous system years before nigrostriatal involvement. Isolated REM sleep behaviour disorder (iRBD) is considered an early manifestation of body-first LBD but is ...
Casper Skjærbæk   +12 more
doaj   +1 more source

A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders

open access: yesNature Communications, 2020
The substantia nigra is important in neurological disease, particularly movement disorders. Here the authors provide a single cell transcriptomic atlas for the human substantia nigra.
Devika Agarwal   +8 more
doaj   +1 more source

Additional file 3: of Blood transcriptomics of drug-naĂŻve sporadic Parkinsonâ s disease patients

open access: yes, 2015
List of the 395 variables selected by Ranking-PCA to discriminate between PD patients and controls. Order of variables, Affymetrix Probe Set IDs, gene symbols and names are indicated. (PDF 3122 kb)
Calligaris, Raffaella   +17 more
openaire   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers   +19 more
wiley   +1 more source

Characteristics of Parkinson’s disease patients.

open access: yes, 2021
Characteristics of Parkinson’s disease patients.
Fredrik Tjernström (11188224)   +6 more
core   +1 more source

Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cutaneous phosphorylated α‐synuclein (p‐syn) and α‐synuclein seeding activity are promising biomarkers for Parkinson's disease (PD), but their clinical value remains uncertain due to disease heterogeneity. This study evaluates these two biomarkers in PD patients to inform phenotype‐specific diagnosis and disease severity assessment ...
Yuting Jin   +8 more
wiley   +1 more source

MOESM1 of A randomized controlled efficacy study of the Medido medication dispenser in Parkinsonâ s disease

open access: yes, 2019
Additional file 1. Table with secondary outcomes of PDQ-39.
Hannink, K.   +8 more
openaire   +1 more source

Home - About - Disclaimer - Privacy